Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial

@article{Baron2008CardiovascularEA,
  title={Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial},
  author={John A. Baron and Robert S. Sandler and Robert S. Bresalier and {\'A}ngel Lanas and Dion G. Morton and Robert Riddell and Erik R Iverson and David L DeMets},
  journal={The Lancet},
  year={2008},
  volume={372},
  pages={1756-1764}
}
Persistence of cardiovascular risk after rofecoxib discontinuation.
TLDR
During a 1-year period of postdrug observation, increased cardiovascular risk associated with rofecoxib use persisted after stopping treatment, which raises concerns about long-term risks incurred by individuals who had taken the drug.
Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case–control study
TLDR
The overall rate of cerebrovascular event was not elevated with current NSAIDs overall when compared with past use, but diclofenac and ketoprofen seemed to increase the risk of cereBrovascular events.
Clinical Pharmacology and Cardiovascular Safety of Naproxen
TLDR
The balance of evidence suggests that cardiovascular risk correlates with cyclooxygenase (COX)-2 selectivity, and the low COX-2Selectivity of naproxen results in a lower cardiovascular risk than that of other NSAIDs.
The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.
TLDR
The cardiovascular risk associated with NSAID treatment was prevalent at start of treatment, suggesting no safe treatment window for NSAIDs in patients with cardiovascular disease, and evidence from observational studies is accumulating, suggesting that NSAIDs are a major public health concern due to the widespread use.
Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults—a nationwide registry-based study
TLDR
This Icelandic nationwide registry-based study showed increased risk of cardiovascular events, i.e. cerebralinfarction, myocardial infarction and unstable angina pectoris, among rofecoxib and naproxen users in comparison to diclofenac users.
Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.
TLDR
Cumulative pooled analysis of all randomized, placebo-controlled trials demonstrates a trend toward increased cardiovascular risk associated with rofecoxib compared with placebo as early as December 2000, the comparison reaching a P value of .05 by June 2001, nearly 3(1/2) years before the manufacturer's voluntary market withdrawal.
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals
TLDR
Individual NSAIDs have different cardiovascular safety that needs to be considered when choosing appropriate treatment and should be used with caution in most individuals, underlines the importance of critical use of NSAID therapy in the general population and that over-the-counter retail of NSAIDs should be reassessed.
Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
TLDR
There is insufficient evidence to conclude that there are significant differences between the approved NSAIDs with regard to the potential for cardiovascular events, and clinicians should continue to use the current FDA NSAID labeling language to guide their decision making for individual patients.
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials.
TLDR
The clinical data and plausible mechanisms of CV hazards associated with traditional NSAIDs and coxibs are discussed, and the use of low-dose aspirin may have a place for chemoprevention of CRCs.
...
...

References

SHOWING 1-10 OF 30 REFERENCES
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
TLDR
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
TLDR
Rofecoxib therapy was associated with an increased frequency of adverse cardiovascular events among patients with a median study treatment of 7.4 months' duration, and died from cardiovascular causes during the follow-up period.
Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas
Background— Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal adenomas but have been associated with increased cardiovascular risk. Methods and Results— The Adenoma Prevention
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
TLDR
It is suggested that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug.
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
TLDR
The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances.
Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
TLDR
In this comprehensive analysis of 114 randomized trials with 116,094 participants, rofecoxib was associated with increased renal and arrhythmia risks and a COX-2 inhibitor class effect was not evident.
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
TLDR
Selective COX 2 inhibitors are associated with a moderate increase in the risk of vascular events, as are high dose regimens of ibuprofen and diclofenac, but high dose naproxen is not associated with such an excess.
A randomized trial of aspirin to prevent colorectal adenomas.
TLDR
Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel, using generalized linear models to compute risk ratios and 95 percent confidence intervals.
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.
TLDR
There was a nonsignificantly higher incidence of developing hypertension compared with nonselective NSAIDs, as was observed with rofecoxib compared with celecoxib, and cyclooxygenase-2 inhibitors were associated with a point-estimate BP elevation compared with placebo and nonselectIVE NSAIDs.
...
...